Protocol Ledger

NCT03870750 · Phase II/III · TERMINATED

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Interventional Phase II/III clinical trial protocol NCT03870750 sponsored by Fred Hutchinson Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-15 Enrollment: 458 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03870750
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)458 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03870750
Protocol FieldVerified Registry Value
NCT IdentifierNCT03870750
Consolidated Lead SponsorFred Hutchinson Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment458 participants (ACTUAL)
Registered Start Date2019-08-15
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fred Hutchinson / UW Medicine across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI